Corporate

Quantoom Biosciences and Chemopharm to collaborate on Malaysian distribution for Ntensify® mano and Ntensify® micro

Nivelles, Belgium / Kuala Lumpur, Malaysia — March 25, 2026 — Quantoom Biosciences, a full-stack RNA partner providing turnkey solutions for…

Quantoom Biosciences Partners with Europa Biosite to Expand Access to Rapid RNA Production Technologies Across Europe

Nivelles, Belgium — March 17, 2026 — Quantoom Biosciences today announced a new distribution partnership with Europa Biosite, a leading…

Quantoom Biosciences and Skybioscience to collaborate on South-Korean distribution for Ntensify® mano and Ntensify® micro

Quantoom Biosciences and Skybioscienc to collaborate on South-Korean distribution for Ntensify® mano and Ntensify® micro Nivelles [Nivelles, Belgium] / [Incheon, South-Korea]…

Quantoom Biosciences Appoints Soter Bio as Exclusive North America RNA CDMO for RUO and GMP Manufacturing

Nivelles, Belgium, and Houston, Texas — February 9, 2026 Quantoom Biosciences, a leader in integrated RNA-CNP manufacturing technologies, today announced…

Afrigen Biologics Complete First Technical Production Run of mRNA Vaccine Against Rift Valley Fever with Quantoom Biosciences Ntensify® technology

Cape Town, South Africa & Brussels, Belgium— December 12th, 2025 Afrigen Biologics and Quantoom Biosciences today announced the successful completion…

University of Western Australia’s RNA Innovation Foundry Selects Quantoom Biosciences’ Ntensify® mini for Advanced RNA Research and Technology

Perth, Australia & Nivelles, Belgium – December 3, 2025 Quantoom Biosciences today announced the adoption of the Ntensify® mini platform…

Quantoom Biosciences Signs Research License and Supply Agreement with Leading Global Cancer Center for mRNA Formulation Technology in Personalized Cancer Therapeutics

Nivelles, Belgium — September 25, 2025 Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading institutions for cancer…

VaxThera and Quantoom Biosciences Achieve Breakthrough in Poultry Vaccination Against Highly Pathogenic Avian Influenza (HPAI) Using Quantoom’s N-Force Toolbox for saRNA

Medellín, Colombia and Nivelles, Belgium – June 23, 2025 VaxThera, a biotechnology company that produce vaccines and biologics, and Quantoom…

TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology

Quantoom’s customers can now access TriLink’s CleanCap mRNA capping technology; Agreement supports future expansion of essential therapeutics & vaccines in…

Inventprise Selects Quantoom Biosciences’ Ntensify® Production Technology to Advance mRNA Vaccine Development

REDMOND, Wash., & NIVELLES, Belgium – May 15, 2025 Inventprise Inc., a clinical-stage vaccine invention company, announced today its selection…

Quantoom Biosciences Announces Collaboration with University of Arizona Health Sciences on mRNA-Based Neoantigen Cancer Vaccine

NIVELLES, Belgium – April 14, 2025 Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics, is…

Quantoom Biosciences and DIANT Pharma Inc. Collaborate to Enhance mRNA Supply Chain Efficiency

Manchester, CT, USA & NIVELLES, Belgium – March 31, 2025 Quantoom Biosciences and DIANT Pharma Inc. are proud to announce…

CAPTIVATE Project Update

March 2025 At the end of February, CAPTIVATE-EU held its annual meeting in Barcelona! Scientists Youlia Serikova and Erica Pasini…

The Pirbright Institute Adopts Quantoom Biosciences’ Ntensify® mini to Advance mRNA Vaccine Research for Livestock Diseases

Pirbright, UK & Nivelles, Belgium – Thursday, March 13, 2025 The Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM), part…

India and Belgium Unite to Advance RNA-Based Vaccines: MoU Signed Between Techinvention and Quantoom Biosciences, in the presence of Her Royal Highness Princess Astrid of Belgium during the Belgian Economic Mission to India

Wednesday, March 5, 2025 TechInvention Lifecare Pvt. Ltd. (TechInvention) is proud to announce a strategic collaboration with Belgium-based Quantoom Biosciences…

Africa and Europe Join Forces to Revolutionize RNA-based Vaccines and Therapeutics Production: MoU Signed Between EVA Pharma, DNA Script, Quantoom Biosciences

Cairo, Egypt – February 5, 2025 – Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a…

Belgium and Brazil Unite to Advance RNA-Based Therapies: MoU Signed Between Bio-Manguinhos/Fiocruz, Quantoom Biosciences, and Univercells in the presence of Her Royal Highness Princess Astrid of Belgium during the Belgian Economic Mission to Brazil

Rio de Janeiro, Brazil – November 29, 2024 – During the Belgian Economic Mission to Brazil, a historic Memorandum of…

ST Pharm and Quantoom Biosciences Announce a First Supply Agreement of SmartCap® under Extended Collaboration to Advance RNA Manufacturing

ST Pharm, a leading technology-driven RNA CDMO, and Quantoom Biosciences (also referred as “Quantoom”), a specialized RNA technology platform developer,…

Corporate • Quantoom Biosciences

Corporate